Credit: Getty Images. The FDA has expanded the approval of Breo Ellipta to include maintenance treatment of asthma in children 5 to 17 years of age. The Food and Drug Administration (FDA) has expanded ...
If you have a certain kind of lung condition, your doctor might suggest Breo Ellipta as a treatment option for you. Breo Ellipta is a prescription drug used to treat chronic obstructive pulmonary ...
Breo Ellipta (fluticasone furoate/vilanterol trifenatate) is a prescription drug used to treat chronic obstructive pulmonary disease (COPD) and asthma. Breo Ellipta’s cost may depend on factors such ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 30, 2015) - GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug ...
DUBLIN--(BUSINESS WIRE)--The "Breo Ellipta" report has been added to ResearchAndMarkets.com's offering. Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol ...
GlaxoSmithKline’s new long-term, once-daily, maintenance therapy for chronic obstructive pulmonary disease (COPD) has been approved in the US. The FDA licensed Breo Ellipta to treat airflow ...
The FDA granted approval to GlaxoSmithKline's ($GSK) new respiratory drug Breo Ellipta. By itself, that's a solid victory for GSK, which needs to build up its ...
GlaxoSmithKline expanded its COPD reach in Europe. The company announced Monday that the European Medicines Agency Committee for Medicinal Products for Human Use—familiarly known as EMA CHMP—approved ...
GlaxoSmithKline plc (LSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO® ELLIPTA® (fluticasone furoate/vilanterol [FF/VI]) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback